Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP4132 in advanced solid tumors and lymphoma
NCT02383368Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Mar 2015
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ASP4132 in solid tumor and lymphoma (2 arms), sponsored by Astellas Pharma. Primary endpoints: Safety as assessed by adverse events up to 39 months, Safety as assessed by clinical laboratory tests up to 39 months and 2 more. Started Mar 2015; status: completed.
02
Drugs
ASP4132
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT02383368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02383368.